Under a contract with Novartis, Harvard Pilgrim will receive a discount from the drug company if its Ernesto treatment for congestive heart failure does not result in a specified drop in patient hospitalizations, according to the article.
Under the other contract, Harvard Pilgrim has agreed to accept a lower rebate from Eli Lilly if its diabetes drug lowers patients’ hemoglobin levels better than drug competitors.
Novartis has already struck outcomes-based contracts for Ernesto with Cigna and Aetna.
More articles on payer issues:
UnitedHealth limits number of in-network insulin pumps, worries consumers
Florida Healthy Kids to end one insurance plan
N.D. insurance commissioner fines Sanford Health Plan over ads
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
